Abstracts tagged "Rheumatoid Factor"

Abstract Number: 505 • 2016 ACR/ARHP Annual Meeting
The Longitudinal Stability of the RA Biomarkers RF and ACPA in Classifying RA Subtypes over Extended Follow up
Carl Orr, Francis Young and Douglas J. Veale, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland
Background/Purpose: In recent years several studies suggest that first order stratification of RA should be based on the presence or absence of rheumatoid factor (RF)…
Abstract Number: 552 • 2016 ACR/ARHP Annual Meeting
Disability in Early Rheumatoid Arthritis, Course and Predictors
Therese Hansson^1,2, Christina Book^1,2, Lennart T.H. Jacobsson^1,3 and Carl Turesson^1,2, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ³Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden
Background/Purpose: Patient reported outcome measures (PROMs), including the Health Assessment Questionnaire Disability Index (HAQ-DI), are valuable and reliable instruments for assessment of disease severity and…
Abstract Number: 579 • 2016 ACR/ARHP Annual Meeting
MRI-Detected Osteitis Is Not Associated with the Presence or Level of ACPA Alone, but with the Combined Presence of ACPA and RF
Debbie M. Boeters¹, Wouter P. Nieuwenhuis¹, Marije K. Verheul¹, Elize C. Newsum¹, Monique Reijnierse², René E.M. Toes¹, Leendert A. Trouw¹ and Annette H.M. van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Within rheumatoid arthritis (RA) bone marrow edema (BME, osteitis) and anti-citrullinated protein antibodies (ACPAs) are associated with radiographic progression. ACPA has been associated with…
Abstract Number: 988 • 2016 ACR/ARHP Annual Meeting
Risk of Rheumatoid Arthritis after Transfusion of Blood from Donors Later Diagnosed with Rheumatoid Arthritis: A Retrospective Cohort Study
Søren Andreas Just¹, Kjell Titlestad², Gustaf Edgren³, Klaus Rostgaard⁴, Johan Askling⁵, Hanne Lindegaard¹ and Henrik Hjalgrim⁴, ¹Department of Rheumatology, Department of Rheumatology, Odense University Hospital, Odense, Denmark, Odense, Denmark, ²Department of Clinical Immunology, Department of Clinical Immunology, Odense Unversity Hospital, Odense, Denmark, Odense, Denmark, ³Department of Medical Epidemiology and Biostatistics, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Epidemiology Research, Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark, Copenhagen, Denmark, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Rheumatoid Arthritis (RA) is a disease that can have a long sub-clinical phase. During this phase the person with pre-RA could have factors in…
Abstract Number: 1589 • 2016 ACR/ARHP Annual Meeting
Body Mass Index Does Not Impact Abatacept Retention in Biologic-Naive Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: A 12-Month Interim Analysis of an Observational, Prospective Study
R Alten¹, H-M Lorenz², HG Nüßlein³, X Mariette⁴, M Galeazzi⁵, A Cantagrel⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³University of Erlangen, Nürnberg, Germany, ⁴Université Paris-Sud, Paris, France, ⁵University of Siena, Siena, Italy, ⁶Purpan Hospital, Toulouse, France, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: In patients with RA, obesity may impair clinical response to anti-TNF agents.1,2 In contrast, BMI does not appear to impact treatment retention or clinical…
Abstract Number: 1603 • 2016 ACR/ARHP Annual Meeting
Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis
Laura Cappelli¹, J. Lynn Palmer² and Clifton Bingham III³, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²CORRONA Research Foundation, Phoenix, AZ, ³Johns Hopkins University, Baltimore, MD
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis Background/Purpose: Biologic medications have improved outcomes for patients with rheumatoid arthritis (RA), but little…
Abstract Number: 2115 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Factors May Potentiate Immune Complex Formation of Anti-Citrullinated Protein Antibodies
Willem J.J. Falkenburg^1,2, Dirkjan van Schaardenburg^3,4, Jana Koers⁵, Pleuni Ooijevaar-de Heer⁵, Gertjan Wolbink^6,7, Arthur E.H. Bentlage⁸, Gestur Vidarsson⁸ and Theo Rispens⁵, ¹Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ²Department of Immunopathology, Sanquin Research, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁵Immunopathology, Sanquin Research, Amsterdam, Netherlands, ⁶Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁸Experimental Immunohematology, Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a complex inflammatory disorder in which autoantibodies play a prominent role. Several types of autoantibodies, including rheumatoid factors (RFs) -…
Abstract Number: 2612 • 2016 ACR/ARHP Annual Meeting
Sero-Positivity for Rheumatoid Factor Is an Independent Predictor for Achievement of Good EULAR Response at 24 Weeks in ACPA Positive Rheumatoid Arthritis Patients Treated with Abatacept: Results from Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Shuji Asai¹ and Naoki Ishiguro², ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University, Nagoya, Japan
Background/Purpose: Abatacept is a new class of biologic agent for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to CD80/86.…
Abstract Number: 2613 • 2016 ACR/ARHP Annual Meeting
Seropositivity for RF or ACPA Predicts Long Term Drug Retention with Rituximab, but Not with Abatacept and Tocilizumab : Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Alain Saraux⁹, Thierry Schaeverbeke¹⁰, Jean Sibilia¹¹, Martin Soubrier¹², Olivier Vittecoq¹³, Elodie Perrodeau¹⁴, Philippe Ravaud¹⁵, Xavier Mariette¹⁶ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Rheumatology, Paris Descartes University, Paris, France, ⁸Rheumatology, University Hospital, Lille, France, ⁹Rheumatology, Brest University Hospital, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹³Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁵Epidemiologist, PARIS, France, ¹⁶Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Seropositivity for RF or ACPA is associated with a better short-term effectiveness and drug retention of abatacept (ABA) and rituximab (RTX). Data are very…
Abstract Number: 26 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study
Joong Kyong Ahn¹, Jiwon Hwang², Hyemin Jeong³, Ji Young Chae⁴, Hyungjin Kim³, Hoon-Suk Cha³ and Eun-Mi Koh³, ¹Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, National Police Hospital, Seoul, Korea, The Republic of, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of
Background/Purpose: Several studies have reported increased overall mortality in association with rheumatoid factor (RF) in RA. However, the clinical significance including health outcomes of RF…
Abstract Number: 27 • 2016 ACR/ARHP Annual Meeting
A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Greater disease severity, older age, positive serum rheumatoid factor (RF), and long-standing glucocorticoid usage contribute to increased mortality of rheumatoid arthritis (RA) patients. This…
Abstract Number: 491 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Peptide Antibodies Testing Rate over Time in Newly Diagnosed RA Patients – Data from Three Administrative Claims Databases (2007–2014)
E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Current clinical guidelines recommend testing for anti-citrullinated protein antibodies (ACPA) at the time of RA diagnosis.1 However, there is a lack of information about…
Abstract Number: 494 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Dmitry Karayev¹, Guoqiu Shen¹, Yvonne Lam¹, Andrew Rimmer¹, Nayan Lal¹, Eugene Karayev¹, Kristine Azarraga¹, Ronald A. Blum¹, Allan L. Metzger¹, Robert I. Morris¹ and Arash A. Horizon², ¹Rheumatology Diagnostics Laboratory, Inc. (RDL), Los Angeles, CA, ²Center for Rheumatology Medical Group, Los Angeles, CA
Background/Purpose: RA is the most common autoimmune inflammatory joint disease, affecting up to 1% of the world population. Detection of antibodies, specifically against IgM rheumatoid…
Abstract Number: 496 • 2016 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes
Ee Tzun Koh¹, Angela Marie Chan¹, Wei Qiang See², Wenwei Xiang², Khai Pang Leong¹ and Tan Tock Seng Rheumatoid Arthritis Study Group, ¹Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ²Clinical Research and Innovation Office, Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: RA Patients with anti-citrullinated protein antibody (ACPA) or rheumatoid factor (RF) are known to have worse clinical outcomes compared to seronegative patients. To determine…
Abstract Number: 1578 • 2015 ACR/ARHP Annual Meeting
Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Associated with Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis: A Population-Based Study
Elana J. Bernstein¹, R. Graham Barr², John H.M. Austin³, Steven M. Kawut⁴, Ganesh Raghu⁵, Jessica L. Sell⁶, Eric A. Hoffman⁷, John D. Newell Jr.⁸, Jubal R. Watts Jr.⁹, P. Hrudaya Nath¹⁰, Sushil K. Sonavane⁹, Joan M. Bathon¹, Darcy S. Majka¹¹ and David J. Lederer², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University College of Physicians & Surgeons, New York, NY, ³Radiology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA, ⁵University of Washington, Seattle, WA, ⁶Columbia University College of Physicians & Surgeons, New York, NY, ⁷University of Iowa, Iowa City, IA, ⁸Radiology, University of Iowa, Iowa City, IA, ⁹Radiology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Division of Rheumatology, Northwestern University, Chicago, IL
Background/Purpose: Approximately 30% of adults diagnosed with interstitial lung disease (ILD) have an underlying established autoimmune disease. Based on the strong links between autoimmunity and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].